Urology Practice Management - September 2021, Vol 7, No 2

Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease. Read More ›

Treatment with the checkpoint inhibitor pembrolizumab (Keytruda) following surgery significantly extended disease-free survival (DFS) in patients with high-risk, clear-cell renal-cell carcinoma (RCC) compared with placebo, according to the results of the KEYNOTE-564 clinical trial. These findings were reported during a plenary session of the ASCO 2021 virtual annual meeting. Read More ›

Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to lifesaving therapies. At the ASCO 2021 virtual annual meeting, Lalan S. Wilfong, MD, Executive Vice President, Value-Based Care and Quality Programs, and Medical Oncologist/Hematologist, Texas Oncology, Presbyterian Cancer Center Dallas, TX, discussed how a community practice model for therapeutic interchange of brand drugs to biosimilars led to a significant increase in utilization of biosimilars and substantial cost-savings over the course of a single year at his institution. Read More ›

For more than 40 years, healthcare professionals, public health advocates, and healthcare strategists have been discussing health inequities that consistently and disproportionately affect groups of color in the United States. Despite growing awareness of these disparities, however, limited progress has been made, according to Lakesha M. Butler, PharmD, BCPS, Diversity and Inclusion Coordinator, Southern Illinois University Edwardsville. Read More ›

The COVID-19 pandemic may have temporarily overshadowed the opioid crisis in the United States, but deaths related to opioid overdose have risen to an all-time high in the past year. Although largely driven by synthetic opioids such as illicit fentanyl, frequently prescribed opioids have played a role in opioid overdose and opioid use disorder as well. Read More ›

The addition of 177Lu-PSMA-617, a radionuclide therapy that targets prostate-specific membrane antigen (PSMA), to standard-of-care treatment resulted in a 38% reduction in the risk for death versus standard of care alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION clinical trial, which were presented during a plenary session at the ASCO 2021 virtual annual meeting. Read More ›

On July 9, 2021, the FDA granted full approval to enfortumab vedotin-ejfv (Padcev; Astellas Pharma), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have received ≥1 previous lines of therapy. Read More ›

Subscribe to
Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or weekly e‑Newsletter.

I'd like to receive: